🚀 VC round data is live in beta, check it out!
Klaria Pharma Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for Klaria Pharma Holding and similar public comparables like Lisata Therapeutics, Lantern Pharma, Jasper Therapeutics, Tempest Therapeutics and more.
Klaria Pharma Holding Overview
About Klaria Pharma Holding
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product’s active substance through the oral mucosa.
Founded
2014
HQ
Employees
4
Website
Sectors
Financials (FY)
EV
$31M
Klaria Pharma Holding Financials
Klaria Pharma Holding reported last fiscal year revenue of $977K and negative EBITDA of ($2M).
In the same fiscal year, Klaria Pharma Holding generated ($2M) in EBITDA losses and had net loss of ($4M).
Klaria Pharma Holding P&L
In the most recent fiscal year, Klaria Pharma Holding reported revenue of $977K and EBITDA of ($2M).
Klaria Pharma Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $977K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (156%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (281%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (433%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Klaria Pharma Holding Stock Performance
Klaria Pharma Holding has current market cap of $29M, and enterprise value of $31M.
Market Cap Evolution
Klaria Pharma Holding's stock price is $0.12.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $31M | $29M | 5.6% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKlaria Pharma Holding Valuation Multiples
Klaria Pharma Holding trades at 32.1x EV/Revenue multiple, and (20.6x) EV/EBITDA.
Klaria Pharma Holding Financial Valuation Multiples
As of April 18, 2026, Klaria Pharma Holding has market cap of $29M and EV of $31M.
Equity research analysts estimate Klaria Pharma Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Klaria Pharma Holding has a P/E ratio of (6.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $29M | XXX | $29M | XXX | XXX | XXX |
| EV (current) | $31M | XXX | $31M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 32.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (20.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (11.4x) | XXX | XXX | XXX |
| P/E | — | XXX | (6.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Klaria Pharma Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Klaria Pharma Holding Margins & Growth Rates
Klaria Pharma Holding's revenue in the last fiscal year grew by 300%.
Klaria Pharma Holding's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.9M for the same period.
Klaria Pharma Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 300% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (156%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (30%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 139% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 223% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 381% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Klaria Pharma Holding Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Klaria Pharma Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Lisata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lantern Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Jasper Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempest Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Elicera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Klaria Pharma Holding M&A Activity
Klaria Pharma Holding acquired XXX companies to date.
Last acquisition by Klaria Pharma Holding was on XXXXXXXX, XXXXX. Klaria Pharma Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Klaria Pharma Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKlaria Pharma Holding Investment Activity
Klaria Pharma Holding invested in XXX companies to date.
Klaria Pharma Holding made its latest investment on XXXXXXXX, XXXXX. Klaria Pharma Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Klaria Pharma Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Klaria Pharma Holding
| When was Klaria Pharma Holding founded? | Klaria Pharma Holding was founded in 2014. |
| Where is Klaria Pharma Holding headquartered? | Klaria Pharma Holding is headquartered in Sweden. |
| How many employees does Klaria Pharma Holding have? | As of today, Klaria Pharma Holding has over 4 employees. |
| Is Klaria Pharma Holding publicly listed? | Yes, Klaria Pharma Holding is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Klaria Pharma Holding? | Klaria Pharma Holding trades under KLAR ticker. |
| When did Klaria Pharma Holding go public? | Klaria Pharma Holding went public in 2015. |
| Who are competitors of Klaria Pharma Holding? | Klaria Pharma Holding main competitors are Lisata Therapeutics, Lantern Pharma, Jasper Therapeutics, Tempest Therapeutics. |
| What is the current market cap of Klaria Pharma Holding? | Klaria Pharma Holding's current market cap is $29M. |
| What is the current revenue of Klaria Pharma Holding? | Klaria Pharma Holding's last fiscal year revenue is $977K. |
| What is the current EV/Revenue multiple of Klaria Pharma Holding? | Current revenue multiple of Klaria Pharma Holding is 32.1x. |
| Is Klaria Pharma Holding profitable? | No, Klaria Pharma Holding is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.